Biotechnology, one of molecular biology’s branches, monitored and intentional manipulation of biological organisms, processes or systems to effectively make or process drugs, or any other products and substances useful to enhancing people’s living quality. The earliest examples of humans applying their knowledge of biotechnology involved the efforts to enhance plants and animals’ species by cross-pollination (allogamy) or cross-breeding.
Biotechnology has recently turned to a more sophisticated business, considerably enlarged in scale and application range. Having goodly restored from the recession, the world Biotechnology Market is anticipated to be eventually estimated at far over EUR 245 billion by end-2015. However, with the numerous benefits this advanced technology comes laden with, there are worries about its potential misuse. Concerns over this issue has trailed into some attempting to facilitate the enforcement of specific laws constraining or even banning relevant programs and research (e.g. human cloning).
The research reports from this Catalogue offer a comprehensive outlook on the worldwide Biotechnology Market. The reports identify major market challenging forces and growth drivers, provide fresh statistics on the Biotechnology Industry, outline various trends and factors specifying the market’s direction, and more. Regional and country markets’ reviews are at hand in the reports too. Furthermore, companies with their innovations are discussed, and also short to long term forecasts are provided in the researches.
Publications found:
1,388
Sort by:
World Biomass Report Ed 1, 2011
US$ 1,445.00
... often transported at great distance, rather than wood chips or other less dense biomass sources. In the wood pellets market, supplies from the US and Canada ... counterparts and thus North America is a major suppli- ers for European biomass plants. CIS countries, Russia, Australia and South Africa have entered ...
September 2012
521 pages
India Biosimilar Market Analysis
US$ 1,000.00
... 4 insulin biosimilars available in the Indian market. The acceptability of biosimilars is higher in the domestic market. Biosimilar substitution is automatic and can take place as soon as a biosimilar is launched. “India Biosimilar Market Analysis” research report by KuicK research gives detailed insight on various aspects related the biosimilar market in India like Market Overview, Biosimilar Pipeline Analysis, Biosimilar Development Capabilities ...
August 2012
80 pages
Stem Cell Research in India 2012
US$ 950.00
The report is sent in 0-2 business days after order is placed. The stem cell research in India is in its nascent stage and is gradually on a growth path of acceptance by ... covers the market size and growth prospect of the stem cell banking market in India. In addition to these, the report gives a snapshot of ...
July 2012
65 pages
Global Biosimilars Market Report: 2012 Edition
US$ 800.00
... lower return on investments continues to challenge the attractiveness of the biosimilars market. The report analyzes the global biosimilars market. The various drivers and challenges faced by the ...
June 2012
40 pages
Generic Testing Market Report: 2012 Edition
US$ 800.00
... to hinder the growth of the market in the coming years. The current report analyzes the genetic testing market. It discusses the drivers and ... challenges prevailing in the genetic testing market. It presents the ...
June 2012
45 pages
Rising Stars (Small-Mid Cap) Biotech/Biopharma: Investment Opportunities
US$ 400.00
... continue in 2012. In this report, we highlight the investment opportunities in the mid-small cap Rising Star companies: ARQL: Key Driver is Tivantinib (c-MET inhibitor) in PhIII for ... of the risk reward please read our report titled, “Rising Stars (Small-Mid Cap) Biotech/Biopharma: Investment Opportunities”.
June 2012
18 pages
The Chinese R&D Landscape - Biotechnology
US$ 1,200.00
R&D in China in the field of biotechnology* has surged over the last decade. This report seeks to answer the following questions related to this surge in R&D:
Where in China does the R&...
May 2012
12 pages
Global Biotech API Market Analysis
US$ 1,000.00
Biotech APIs contribute a very low share in the global API market with synthetic API’s accounting for majority of the formulations. However, with the revolutionary growth in the biopharmaceutical indu...
May 2012
60 pages
Biogen: Teriflunomide Does Not TOWER Over BG-12!
US$ 90.00
Top-line data from PhIII trial, TOWER of Sanofi’s Aubagio (teriflunomide, R, RRMS, PDUFA: 3Q12) reaffirms our take on BG-12 (Dimethyl fumerate, R, Est. ... details, please read our report released on June 1st , 2012 on Biogen (BIIB), titled “Teriflunomide Does Not TOWER Over BG-12”
May 2012
4 pages
Biotechnology in India: Market Research Report
US$ 3,950.00
This report analyzes the market for Biotechnology in India in US$ million by the following Key Sectors: Bio-Pharmaceuticals, Bio-Agriculture, Bio-Industrial, ... , Lambda Therapeutic Research Ltd., Mahyco, Max Neeman, Monsanto, Novo Nordisk India Pvt.Ltd., Novozymes South Asia Pvt.Ltd., Nuziveedu Seeds Pvt.Ltd., ...
April 2012
396 pages
Indian Bioinformatics Market Forecast to 2015
US$ 500.00
Bioinformatics is one of the fastest emerging interdisciplinary research areas, which may be defined as an ‘interface between biological and computational sciences’. Most of the Bioinformatics work ca...
April 2012
35 pages
EPO Biosimilars Market Forecast to 2015
US$ 300.00
The biosimilars industry has been growing stupendously across the globe for the past few years. Increasing healthcare costs and rising aging population are driving the industry, which stands at a vivi...
April 2012
34 pages
G-CSF Biosimilars Market Forecast to 2015
US$ 300.00
For the past few years, the biosimilars industry has been growing stupendously across the globe due to increasing healthcare costs and rising aging population. It is expected to evolve, to a great ext...
April 2012
35 pages
HGH Biosimilars Market Forecast to 2015
US$ 300.00
Across the globe, the biosimilars industry has been growing stupendously for the past few years. Increasing healthcare costs and rising aging population are driving the industry that is expected to ev...
April 2012
35 pages
Lupin - Generic Fortamet Launched At Last, However Low Competition Window Shrinks
US$ 140.00
We withdraw our Positive Investment Alert (PIA) on Lupin after it re-launched generic Fortamet ($83m of annual US sales) in the US market. We issued ... the Preliminary Injunction (PI) on Lupin’s generic Fortamet. While we expected Lupin to launch it soon after the ruling, Lupin waited for the Federal Circuit ...
April 2012
3 pages
Merck - Celltrion filed first mAB Biosimilar in Europe: Remicade Challenged
US$ 90.00
Celltrion filed infliximab biosimilar (CT-P13) in Europe and was accepted for review by EMA. It is the first biosimilar mAb to be filed for approval in Europe. The patent ... Celltrion conducted PhI and PhIII clinical trials with the duration of 12 months in more than 850 patients. It has already filed Infliximab ...
April 2012
1 pages
Biotechnology Reagents: Market Research Report
US$ 4,500.00
... analyzes the worldwide markets for Biotechnology Reagents in US$ Million by the following Product Segments: Cell/Tissue Culture Reagents, DNA Sequencing/Synthesis ... Diagnostics Ltd., Siemens Healthcare Diagnostics, Inc., and Sigma - Aldrich. Market data and analytics are derived from primary and secondary ...
March 2012
925 pages
Branded Generics in South East Asia: Current and Future Opportunities
US$ 945.00
... launching their branded generic brands but I can't say for sure that success is guaranteed in South East Asia.” – Dr. Suchitra Kataria, former Head of Business Development and In-Licensing - Regional Strategic Development Asia Pacific at Bayer ...
March 2012
78 pages
Generics as a Vehicle to Improve Market Access
US$ 695.00
In low and middle-income countries, around 17.6 million people each year die of treatable infectious diseases, reproductive health issues, and childhood illnesses. Millions more experience poor qualit...
March 2012
79 pages
Assessment of the Japan Generics Industry
US$ 800.00
Executive
While Japan is the second largest pharma market globally, it has a very low penetration rate of generic drugs. The country’s government has set an ambitious goal to enhance the generic...
March 2012
25 pages
Moving Bed Bioreactor (MBBR): Market Research Report
US$ 4,600.00
This report analyzes the worldwide markets for Moving Bed Bioreactor (MBBR) in US$ Million by the following End-Use Applications: Municipal, Food and ... Water Solutions & Technologies, Wock-Oliver, Inc., and World Water Works, Inc. Market data and analytics are derived from primary and secondary research. ...
February 2012
222 pages
Global Biosimilars Market Forecast to 2015
US$ 1,500.00
The biosimilars industry has been growing stupendously across the globe for past few years. Increasing healthcare costs and rising aging population are driving the industry, which stands at a vivid po...
February 2012
140 pages
Generic Defence Strategies: Targeting Patient Co-Pay
US$ 695.00
Coupons for co-pays are fast becoming a standard part of the brand marketer’s toolkit, due to proven positive ROI. It’s projected that by 2017, coupons will be associated with 30% of all U.S. prescrip...
February 2012
41 pages
Japan Generics Market Analysis
US$ 1,000.00
Japan is the world’s second largest pharmaceutical markets in the world, but due to public perception, the share of generic drugs has remained low in it. However, worried over rising healthcare expens...
February 2012
55 pages
Canada’s Biotechnology Industry - Porter’s Five Forces Strategy Analysis
US$ 175.00
... is a critical element of national power. Advances in biotechnology are resulting in novel biomedical and pharmaceutical products and processes ... the world’s citizens. Aruvian's R'search analyzes the Canadian Biotechnology industry in the Michael Porter’s Five Forces Analysis. It uses concepts developed in ...
February 2012
20 pages
Japan’s Biotechnology Industry - Porter’s Five Forces Strategy Analysis
US$ 175.00
... is a critical element of national power. Advances in biotechnology are resulting in novel biomedical and pharmaceutical products and processes ... the world’s citizens. Aruvian's R'search analyzes the Japanese Biotechnology Industry in the Michael Porter’s Five Forces Analysis. It uses concepts developed in ...
February 2012
20 pages
Looking at Bioinformatics – IT’s Human Touch
US$ 275.00
... ranging industries and research applications. The growing acceptance of Bioinformatics as an important field requiring focused commercial support and ... in order to expand the service bases. Aruvian's R'search’s report – Looking at Bioinformatics – IT’s Human Touch - is a analytical docket on the Bio Informatics ...
February 2012
85 pages
Competitor Analysis: Anti-Obesity Peptides and Biologics
US$ 262.00
... peptides and biologics as of February 2012. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and ... . In addition, the report lists company-specific R&D pipelines of anti-obesity peptides and biologics. Competitor projects are listed in a tabular format providing ...
February 2012
28 pages
LUPIN - Generic Tricor To Offer a Cushion Against Suprax Generic Erosion
US$ 140.00
... multiple years. In addition, there is a strong likelihood that Lupin may remain the only generic player for some time – something that we have ... for Suprax from FY13 to FY14 and (2) estimating $40m from generic Tricor in FY14 (to be launched in Q4 FY13). We upgrade our target price to Rs.463 by applying ...
January 2012
6 pages
European Biotechnology Directory 2012 - 2013
US$ 200.00
PDF version is dispatched within twenty-four hours after the purchase. PDF option available starting May, 20 The European Directory of Biotechnology Companies 2012-13 is one of the most comprehensive...
January 2012
